ARTV Artiva Biotherapeutics, Inc.
USHealthcareAs of 2026-08-24
Why ARTV matters now
Artiva Biotherapeutics, Inc. (ARTV) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.52 with +5.40% on the session and $563.2M in market capitalization; recent performance reads 1-month +14.85% and YTD +128.90%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-23.5M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -33.0%.
The latest indexable market news headline is "Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $37.50; recent insider activity includes RA CAPITAL MANAGEMENT, L.P. filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.76
P/S
0.00
EV/EBITDA
-2.75
DCF Value
$0.66
FCF Yield
-33.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.2%
ROA
-82.2%
ROIC
-93.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-23.5M | $-0.95 |
| Q4 2025 | $0.00 | $-20.8M | $-0.85 |
| FY 2025 | $0.00 | $-83.9M | $-3.43 |
| Q3 2025 | $0.00 | $-21.5M | $-0.88 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$37.50
Target (Median)
$37.50
Target Range
$35.00 - $40.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.40
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.